We interviewed 3 KOLs in the 7 days following the CheckMate-026 shake-up to find out how it will impact NSCLC treatment. Disappointing CheckMate-026 trial results may have sidelined Opdivo, creating a huge opportunity for rival Keytruda, and other immunotherapies.
Can one of them corner the market? Will immunotherapy combinations threaten their market share? Is there still hope for Opdivo in the first-line setting?
Novartis' Sandoz unit on Tuesday announced that the FDA authorised Erelzi (etanercept-szzs) as a biosimilar version of Amgen's Enbrel (etanercept) for all indications for which the original... Read More >>